Rx&D Welcomes its Newest Member: KalGene Pharmaceuticals Inc.

By Guest Column —— Bio and Archives May 26, 2011

Comments | Print This | Subscribe | Email Us

OTTAWA, Canada's Research-Based Pharmaceutical Companies (Rx&D) President Russell Williams is pleased to announce today the addition of KalGene Pharmaceuticals Inc. as a new biopharmaceutical member to the association, representing the innovative pharmaceutical industry in Canada. KalGene Pharmaceuticals Inc. is a privately-held Canadian company focused on the development of oncology therapeutics and companion diagnostics with facilities located in Ontario and British Columbia.

KalGene Pharmaceuticals Inc.'s oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on breast, epithelial and thyroid cancers. KalGene is partnering with many of North America's leading clinician-scientists and academic institutions to deliver individualized cancer diagnostics and drugs that maximize positive patient treatment outcomes. "We are pleased to join Rx& D and its mission to develop products that save lives and improve health care outcomes, said Dr. T. Nathan Yoganathan, President and CSO. "Becoming a member of the association will enable us to better advance our goals to discover and develop cancer and diagnostic treatments through the power of personalized medicines". "We welcome KalGene Pharmaceuticals Inc. as the newest member to our association," said Rx&D President Russell Williams. "We look forward to working together to grow Canada's life sciences sector to produce better health outcomes and strengthen our knowledge economy."